Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 5/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.67 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | DRD1 | P21728 | 2/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.67 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.67 |
| ▸ | DRD3 | P35462 | 2/20 | 0.67 |
| ▸ | HTR1A | P08908 | 2/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | HTR7 | P34969 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | BLM | P54132 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16679636 | 1.00 | ADRB1 (0.67) | ADRB1ADRB3ADRB2HIF1AADRA2A | |
| SCHEMBL13986541 | 0.84 | ADRB3 (0.55) | ADRB1ADRB3ADRB2LMNASLC2A1 | |
| SCHEMBL24302767 | 0.83 | SLC6A4 (0.54) | ADRB1ADRB3ADRB2HIF1AADRA2A | |
| SCHEMBL9640610 | 0.83 | ADRB1 (0.66) | ADRB1ADRB3ADRB2HIF1ATSHR | |
| SCHEMBL10876266 | 0.83 | LMNA (0.69) | ADRB1ADRB3ADRB2HIF1ALMNA | |
| SCHEMBL29493213 | 0.83 | ADRB1 (0.66) | ADRB1ADRB3ADRB2HIF1ATSHR | |
| SCHEMBL16559342 | 0.83 | SLC6A2 (0.60) | ADRB1ADRB3ADRB2HIF1AADRA2A | |
| Dimethylamine SCHEMBL27944752 | 0.82 | LMNA (0.52) | ADRB1ADRB3ADRB2HIF1AADRA2A | |
| SCHEMBL27824903 | 0.82 | SLC6A3 (0.60) | ADRB1ADRB3ADRB2HIF1AADRA2A | |
| SCHEMBL12186388 | 0.81 | ADRB3 (0.57) | ADRB1ADRB3ADRB2HIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105658646-B | Aminoheteroaryl benzamide as kinase inhibitor | 诺华股份有限公司 | 2018-11-27 | — | — | CN | disclosed |
| EP-3063143-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2016-09-07 | — | — | EP | disclosed |
| CN-105658646-A | Aminoheteroaryl benzamides as kinase inhibitors | 诺华股份有限公司 | 2016-06-08 | — | — | CN | disclosed |
| WO-2015066188-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | WO | disclosed |
| WO-2012064269-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES | ASTRAZENECA AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064269-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES | ASTRAZENECA AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-7112605-B2 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | Research Institute of Materia Medica Chinese Acadamy of Medical Sciences (CN) | 2006-09-26 | — | — | US | disclosed |
| US-20040029951-A1 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | RESEARCH INSTITUTE OF MATERIAL MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES; | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029951-A1 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | PTGS1, PTGS2, PTGER1 | ADRB1 881/4885ADRB3 587/4885ADRB2 768/4885 |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | APP, BACE1, PSEN1 | ADRB1 162/4885ADRB3 230/4885ADRB2 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.